RA CAPITAL MANAGEMENT, LLC

Average Profitability
<0.0001%
Insider Buys Quantity
145
Insider Buys Sum
$1.8B
Insider Sells Quantity
71
Insider Sells Sum
$214.98M

Insider Activity of RA CAPITAL MANAGEMENT, LLC

According to the SEC Form 4 filings, RA CAPITAL MANAGEMENT, LLC, being in a position of

  1. at 89bio, Inc.,
    оver the last 12 months, has bought 1350000 shares for $20.72M, and sold 0 shares,
    over all time since 2019-11-11, has bought 11593389 shares for $214.16M, and sold 0 shares.

The largest purchase of all time was on 2020-07-14 and amounted to 6666666 shares of Nkarta, Inc. for $120M.

The largest sale of all time was on 2021-03-11 and amounted to 710000 shares of Phathom Pharmaceuticals, Inc. for $31.06M.

Biography of RA CAPITAL MANAGEMENT, LLC

No biography is available at this moment.

2024-11-08PurchaseTyra Biosciences, Inc.
TYRA
1.22M
2.3305%
$16.25$19.84M-2.54%
2024-10-18PurchaseJanux Therapeutics, Inc.
JANX
1.2M
2.0576%
$44.75$53.7M+8.36%
2024-09-16PurchaseBicara Therapeutics Inc. Common Stock
BCAX
1.83M
2.6517%
$18.00$32.99M-16.88%
2024-08-09SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
3.53M
7.6298%
$1.08$3.81M+3.88%
2024-06-17PurchaseAerovate Therapeutics, Inc.
AVTE
928,110
0.2418%
$1.67$1.55M+23.64%
2024-03-27PurchaseNkarta, Inc.
NKTX
3M
5.4767%
$10.00$30M-49.57%
2024-03-27PurchaseARS Pharmaceuticals, Inc.
SPRY
505,954
0.3513%
$9.79$4.95M+13.81%
2024-03-26PurchaseARS Pharmaceuticals, Inc.
SPRY
457,745
0.31%
$9.55$4.37M+13.3%
2024-03-25PurchaseARS Pharmaceuticals, Inc.
SPRY
437,600
0.2811%
$9.06$3.96M+23.33%
2024-03-04Purchase89bio, Inc.
ETNB
1.35M
1.6718%
$15.35$20.72M-36.83%
2024-02-09PurchasePepGen Inc.
PEPG
2.56M
10.4935%
$10.64$27.21M-19.17%
2024-01-11PurchaseSolid Biosciences Inc.
SLDB
904,160
3.235%
$5.53$5M+2.29%
2023-12-11PurchaseWave Life Sciences Ltd.
WVE
1M
1.2134%
$5.00$5M+40.05%
2023-09-21PurchaseARS Pharmaceuticals, Inc.
SPRY
director
2.7M
0.5803%
$3.03$8.18M+131.88%
2023-08-29PurchaseARS Pharmaceuticals, Inc.
SPRY
director
3.75M
1.6487%
$6.20$23.25M+14.03%
2023-08-18PurchaseAN2 Therapeutics, Inc.
ANTX
10 percent owner
1.78M
32.0656%
$9.00$16M-66.55%
2023-07-21PurchaseAcumen Pharmaceuticals, Inc.
ABOS
5.16M
13.1759%
$7.75$40M-51.62%
2023-07-19PurchaseJanux Therapeutics, Inc.
JANX
495,008
1.1638%
$12.46$6.17M-13.24%
2023-07-05PurchaseBlack Diamond Therapeutics, Inc.
BDTX
director
935,850
2.639%
$5.00$4.68M-26.34%
2023-03-24Purchase89bio, Inc.
ETNB
2.46M
4.6238%
$16.25$40M-7.38%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.